文献速递外周动脉疾病

间充质基质细胞在截肢患者中的临床与组织学分析(CHAMP)试验的基本原理与设计:探讨间充质基质细胞治疗严重肢体缺血的治疗机制

Rationale and design of the Clinical and Histologic Analysis of Mesenchymal Stromal Cells in AmPutations (CHAMP) trial investigating the therapeutic mechanism of mesenchymal stromal cells in the treatment of critical limb ischemia.
PubMed 文献 · J Vasc Surg · 2018-02-01

CHAMP为1/2期试验,拟纳入32例需膝下截肢的严重肢体缺血患者,随机接受同种异体间充质基质细胞(CHAMP,n=16)或自体浓缩骨髓穿刺液(marrowCHAMP,n=16)肌内注射,并在注射后第3、7、14、21天行截肢以分析治疗机制。目前已有10例按方案治疗,预计24个月内完成随访。

要点

  • CHAMP为1/2期试验,评估同种异体间充质基质细胞与自体浓缩骨髓穿刺液在严重肢体缺血需膝下截肢患者中的安全性及治疗机制。
  • 拟纳入32例肢体,CHAMP组接受同种异体间充质基质细胞(n=16),marrowCHAMP组接受自体浓缩骨髓穿刺液(n=16)。
  • 注射后随机分配至第3、7、14、21天截肢,取肌肉分析血管生成细胞因子、间充质基质细胞滞留、血管生成造血祖细胞及组织学。

核心结论

  • CHAMP将对同种异体间充质基质细胞和自体浓缩骨髓穿刺液在缺血骨骼肌中的安全性、疗效及治疗机制进行关键性表征。

研究设计与样本

  • CHAMP为正在进行的1/2期试验,CHAMP与平行marrowCHAMP试验合计纳入32例有静息痛或组织缺损需膝下截肢的肢体。
  • CHAMP组(n=16)接受同种异体间充质基质细胞肌内注射,marrowCHAMP组(n=16)接受自体浓缩骨髓穿刺液肌内注射。
  • 注射沿膝下截肢肌皮瓣分布及胫骨前肌近端进行,治疗后随机分配至注射后第3、7、14、21天行截肢。
  • 截肢时从胫骨注射部位以2厘米递增采集骨骼肌,用于分析促血管生成细胞因子、间充质基质细胞滞留、促血管生成造血祖细胞定量及组织学。

主要发现

  • 目前已有10例患者按方案接受治疗,预计24个月内完成全部随访。
  • 临床肢体灌注将在治疗前后通过经皮氧测定、趾臂指数、踝臂指数和吲哚菁绿血管造影定量评估。
  • 其他临床终点包括治疗后6个月随访期间的全因死亡率、截肢修整需求及坏疽发生率。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Currently, there are no accepted nonsurgical therapies that improve the delivery of blood-derived nutrients to patients with critical limb ischemia. Here, we describe the ongoing phase 1/2 Clinical and Histologic Analysis of Mesenchymal Stromal Cells in AmPutations (CHAMP) trial, which will provide crucial evidence of the safety profile of mesenchymal stromal cells (MSCs) and explore their therapeutic mechanisms in the setting of critical limb ischemia requiring below-knee amputation (BKA). METHODS: In the CHAMP and the parallel marrowCHAMP trials (hereafter grouped together as CHAMP), a total of 32 extremities with rest pain or tissue loss requiring BKA will be enrolled to receive intramuscular injections of allogeneic MSCs (CHAMP; n = 16) or autogenous concentrated bone marrow aspirate (marrowCHAMP; n = 16) along the distribution of the BKA myocutaneous flap and proximal tibialis anterior. After treatment, subjects are randomized to BKA at four time points after injection (days 3, 7, 14, and 21). At the time of amputation, skeletal muscle is collected at 2-cm increments from the tibialis injection site and used to determine proangiogenic cytokine description, MSC retention, quantification of proangiogenic hematopoietic progenitor cells, and histologic description. Clinical limb perfusion before and after treatment will be quantified using transcutaneous oximetry, toe-brachial index, ankle-brachial index, and indocyanine angiography. Additional clinical end points include all-cause mortality, need for amputation revision, and gangrene incidence during the 6-month post-treatment follow-up. RESULTS: Enrollment is under way, with 10 patients treated per protocol thus far. We anticipate full conclusion of follow-up within the next 24 months. CONCLUSIONS: CHAMP will be pivotal in characterizing the safety, efficacy, and, most important, therapeutic mechanism of allogeneic MSCs and autogenous concentrated bone marrow aspirate in ischemic skeletal muscle.

来源:J Vasc Surg,查看原文。版权归原作者所有。

引用

  1. Wang SK, Green LA, Drucker NA, et al. Rationale and design of the Clinical and Histologic Analysis of Mesenchymal Stromal Cells in AmPutations (CHAMP) trial investigating the therapeutic mechanism of mesenchymal stromal cells in the treatment of critical limb ischemia. J Vasc Surg. 2018. PMID: 29395424. doi:10.1016/j.jvs.2017.09.057

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。